These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

490 related articles for article (PubMed ID: 31524347)

  • 1. Novel Tretinoin 0.05% Lotion for the Once-Daily Treatment of Moderate-to-Severe Acne Vulgaris in an Asian Population.
    Han G; Armstrong AW; Desai SR; Guenin E
    J Drugs Dermatol; 2019 Sep; 18(9):910-916. PubMed ID: 31524347
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel Tretinoin 0.05% Lotion for Once-Daily Treatment of Moderate-to-Severe Acne Vulgaris in a Hispanic Population.
    Cook-Bolden FE; Weinkle SH; Guenin E; Bhatt V
    J Drugs Dermatol; 2019 Jan; 18(1):32-38. PubMed ID: 30681791
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tretinoin 0.05% Lotion for the Once-Daily Treatment of Moderate-to-Severe Acne Vulgaris: Impact of Gender and Race on Efficacy and Safety.
    Lain E; Day D; Harper J; Guenin E
    J Drugs Dermatol; 2019 Nov; 18(11):1128-1138. PubMed ID: 31741356
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tretinoin 0.05% Lotion for the Once-Daily Treatment of Moderate and Severe Acne Vulgaris in Females: Effect of Age on Efficacy and Tolerability.
    Stein Gold L; Pariser DM; Guenin E
    J Drugs Dermatol; 2019 Dec; 18(12):1218-1225. PubMed ID: 31860209
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel Tretinoin 0.05% Lotion for the Once-daily Treatment of Moderate-to-Severe Acne Vulgaris in an Adult and Adolescent Female Population.
    Kircik LH; Baldwin H; Lain E; Guenin E; Harris S; Bhatt V
    J Drugs Dermatol; 2019 Feb; 18(2):178-188. PubMed ID: 30811141
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Tolerability of a Novel Tretinoin 0.05% Lotion for the Once-Daily Treatment of Moderate or Severe Acne Vulgaris in Adult Females.
    Harper JC; Baldwin H; Stein Gold L; Guenin E
    J Drugs Dermatol; 2019 Nov; 18(11):1147-1154. PubMed ID: 31741360
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel tretinoin 0.05% lotion for the once-daily treatment of moderate-to-severe acne vulgaris in a preadolescent population.
    Eichenfield LF; Sugarman JL; Guenin E; Harris S; Bhatt V
    Pediatr Dermatol; 2019 Mar; 36(2):193-199. PubMed ID: 30656753
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tazarotene 0.045% Lotion for the Once-Daily Treatment of Moderate-to-Severe Acne Vulgaris in Adult Males.
    Cook-Bolden FE; Gold MH; Guenin E
    J Drugs Dermatol; 2020 Jan; 19(1):78-85. PubMed ID: 32023013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel Polymeric Lotion Formulation of Once-Daily Tazarotene (0.045%) for Moderate-to-Severe Acne: Pooled Phase 3 Analysis.
    Tanghetti EA; Werschler WP; Lain E; Guenin E; Harris S; Loncaric A; Pillai R
    J Drugs Dermatol; 2020 Mar; 19(3):272-279. PubMed ID: 32549090
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel Tretinoin 0.05% Lotion for the Once-Daily Treatment of Moderate-to-Severe Acne Vulgaris: Assessment of Efficacy and Safety in Patients Aged 9 Years and Older.
    Tyring SK; Kircik LH; Pariser DM; Guenin E; Bhatt V; Pillai R
    J Drugs Dermatol; 2018 Oct; 17(10):1084-1091. PubMed ID: 30365589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Effects of Once-Daily Tretinoin 0.05% Lotion on Quality of Life in Patients with Moderate-to-Severe Acne Vulgaris.
    Tyring SK; Kircik L; Pariser DM; Woolery-Lloyd HC; Harper JC; Bhatt V; Pillai R; Guenin E
    Am J Clin Dermatol; 2020 Dec; 21(6):891-899. PubMed ID: 32886337
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tazarotene 0.045% Lotion for Once-Daily Treatment of Moderate-to-Severe Acne Vulgaris: Results from Two Phase 3 Trials.
    Tanghetti EA; Werschler WP; Lain T; Guenin E; Martin G; Pillai R
    J Drugs Dermatol; 2020 Jan; 19(1):70-77. PubMed ID: 31985914
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Once-Daily Polymeric Tazarotene 0.045% Lotion for Moderate-to-Severe Acne: Pooled Phase 3 Analysis by Sex.
    Kircik LH; Gold LS; Beer K; Tan J; Baldwin H; Guenin E; Kang R; Varughese J
    J Drugs Dermatol; 2020 Aug; 19(8):777-783. PubMed ID: 32845584
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Phase 2, Multicenter, Double-Blind, Randomized, Vehicle-Controlled Clinical Study to Compare the Safety and Efficacy of a Novel Tazarotene 0.045% Lotion and Tazarotene 0.1% Cream in the Treatment of Moderate-to-Severe Acne Vulgaris.
    Tanghetti EA; Kircik LH; Green LJ; Guenin E; Harris S; Martin G; Pillai R
    J Drugs Dermatol; 2019 Jun; 18(6):542. PubMed ID: 31251546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New Polymeric Once-Daily Tazarotene 0.045% Lotion Formulation for Moderate-to-Severe Acne: Pooled Phase 3 Pediatric Analysis.
    Eichenfield LF; Tanghetti EA; Guenin E; Martin G; Pillai R
    J Drugs Dermatol; 2020 Jun; 19(6):602-610. PubMed ID: 32574011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel tretinoin 0.05% lotion for the once-daily treatment of moderate-to-severe acne vulgaris: assessment of safety and tolerability in subgroups.
    Harper JC; Roberts WE; Zeichner JA; Guenin E; Bhatt V; Pillai R
    J Dermatolog Treat; 2020 Mar; 31(2):160-167. PubMed ID: 30935257
    [No Abstract]   [Full Text] [Related]  

  • 17. Novel Tretinoin 0.05% Lotion for the Once-daily Treatment of Moderate-to-severe Acne Vulgaris in a Preadolescent and Adolescent Population.
    St Surin-Lord S; Schlesinger TE; Guenin E
    J Clin Aesthet Dermatol; 2019 Sep; 12(9):E57-E61. PubMed ID: 31641421
    [No Abstract]   [Full Text] [Related]  

  • 18. Novel Polymeric Tazarotene 0.045% Lotion for Moderate-to-Severe Acne: Pooled Phase 3 Analysis by Race/Ethnicity.
    Bhatia N; Weiss JS; Sadick N; Cook-Bolden FE; Tyring SK; Guenin E; Loncaric A; Harris S
    J Drugs Dermatol; 2020 Jul; 19(7):727-734. PubMed ID: 32726105
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of Tazarotene 0.045% Lotion on Quality of Life in Patients With Moderate-to-Severe Acne.
    Kircik LH; Lain E; Gold M; Katz B; Baldwin H; Guenin E; Loncaric A; Pillai R
    J Drugs Dermatol; 2020 Nov; 19(11):1086-1092. PubMed ID: 33196747
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tazarotene 0.045% Lotion for Moderate-to-Severe Acne Patients: Pooled Phase 3 Analysis by Age and Sex.
    Green LJ; Del Rosso JQ; Tanghetti EA; Guenin E
    J Drugs Dermatol; 2021 Jun; 20(6):608-615. PubMed ID: 34076400
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.